|
|
|
|
Lonza's comprehensive AAV analytical package not only offers insights into viral genome titer but also provides valuable information on its integrity and identity. This cost-effective approach, akin to the setup of traditional 1D or 2D dPCR, holds the potential to advance the application of rAAV in cell and gene therapy for the treatment of human diseases.
|
|
|
|
|
Explore the benefits of using mRNA for vaccines and therapeutics, and review emerging mRNA production technologies. We address some technical, intellectual property (IP), and cost considerations, particularly when considering commercial production, and illustrate how partnering in early clinical stages may help to access a reliable production workflow.
|
|
|
|
|
Lonza’s transient transfection platform consistently delivers industry-leading AAV titers, high full/empty capsid ratio, and overall yield. Proprietary suspension HEK293 cell line and plasmids, manufacturing processes, and analytics are integrated to generate a scalable platform with proven performance using multiple serotypes and transgenes.
|
|
|
|
|
Transient transfection often struggles with reproducibility, scalability, and consistently high yields. Achieve reliable, high-titer AAV manufacturing with a scalable, serotype-agnostic transient transfection platform. Deliver high-quality vectors with 78–94% full capsids, accelerating your program from development to clinical milestones.
|
|
|
|
|
|
mRNA/LNP Development And Manufacturing Services
|
Accelerate your mRNA program by leveraging a unified, end-to-end service network. Master the complexities of cGMP development, from DNA template supply and LNP encapsulation to final fill/finish. Simplify your regulatory strategy and reduce financial exposure through a unified network.
|
|
• Request Information
|
|
|
|
|
|
|
|
